Tenaya Therapeutics, Inc. financial data

Symbol
TNYA on Nasdaq
Location
171 Oyster Point Blvd., Suite 500, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 548 % -9.5%
Debt-to-equity 24 % +24%
Return On Equity -93.8 % -15.9%
Return On Assets -75.7 % -11.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 163M shares +107%
Common Stock, Shares, Outstanding 86.5M shares +26.7%
Entity Public Float 171M USD -37.2%
Common Stock, Value, Issued 16K USD +100%
Weighted Average Number of Shares Outstanding, Basic 163M shares +89.9%
Weighted Average Number of Shares Outstanding, Diluted 163M shares +89.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 77.5M USD -17.3%
General and Administrative Expense 25.5M USD -23.4%
Operating Income (Loss) -103M USD +18.9%
Nonoperating Income (Expense) 3.37M USD -45.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -99.6M USD +17.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -99.6M USD +17.5%
Earnings Per Share, Basic 0 USD/shares +38.3%
Earnings Per Share, Diluted 0 USD/shares +38.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 62.7M USD +7.8%
Cash, Cash Equivalents, and Short-term Investments 71.7M USD -27.8%
Other Assets, Current 218K USD -84.5%
Assets, Current 75.9M USD -27.8%
Property, Plant and Equipment, Net 31.3M USD -20.7%
Operating Lease, Right-of-Use Asset 10.7M USD -21.8%
Other Assets, Noncurrent 4.31M USD -14.9%
Assets 122M USD -25.1%
Accounts Payable, Current 3.3M USD -23.7%
Accrued Liabilities, Current 6.52M USD -27.8%
Liabilities, Current 12.7M USD -24.3%
Operating Lease, Liability, Noncurrent 9.38M USD -23.2%
Other Liabilities, Noncurrent 293K USD +10.2%
Liabilities 22.3M USD -23.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1K USD +98.5%
Retained Earnings (Accumulated Deficit) -565M USD -21.4%
Stockholders' Equity Attributable to Parent 99.8M USD -25.5%
Liabilities and Equity 122M USD -25.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.1M USD +19.4%
Net Cash Provided by (Used in) Financing Activities 50.3M USD +7.46%
Net Cash Provided by (Used in) Investing Activities 22.3M USD
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 86.5M shares +26.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 49.4M USD +263%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 63.1M USD +7.75%
Deferred Tax Assets, Valuation Allowance 126M USD +24.7%
Deferred Tax Assets, Gross 130M USD +24.3%
Operating Lease, Liability 12.2M USD -21.6%
Payments to Acquire Property, Plant, and Equipment 383K USD -32.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -99.6M USD +17.4%
Lessee, Operating Lease, Liability, to be Paid 15M USD -23.3%
Property, Plant and Equipment, Gross 68.3M USD +0.41%
Operating Lease, Liability, Current 2.83M USD -15.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.78M USD -2.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.86M USD +0.08%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.8M USD -30.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.47M USD -61%
Deferred Tax Assets, Operating Loss Carryforwards 66.6M USD +26.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 6.36M USD +40.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.52M USD +2.99%
Operating Lease, Payments 989K USD -25.8%
Additional Paid in Capital 664M USD +10.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.66M USD +23.5%
Deferred Tax Assets, Net of Valuation Allowance 3.39M USD +11.7%
Share-based Payment Arrangement, Expense 15M USD -10.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%